Last reviewed 2026-06-01 · How we verify

LEUCINOCAINE

Phase 2 active Small molecule ✓ Verified Jun 2026

LEUCINOCAINE is a leucinocaine drug. It is currently in Phase 2 development.

Leucinocaine is thought to work by interacting with a specific target in the body, but its exact mechanism is not yet understood.

Leucinocaine is a small molecule drug in the leucinocaine class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, there is limited information available on its safety profile and pharmacokinetic properties. Further research is needed to fully understand the properties and potential uses of leucinocaine. Its current owner and development history are also unknown.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LEUCINOCAINE
Drug class	leucinocaine
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and leucinocaine is a key that fits into one of those locks. When it binds to the lock, it can either block or enhance the activity of the cell. However, the exact lock that leucinocaine fits into is still a mystery.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LEUCINOCAINE CI brief — competitive landscape report
LEUCINOCAINE updates RSS · CI watch RSS

Frequently asked questions about LEUCINOCAINE

What is LEUCINOCAINE?

LEUCINOCAINE is a leucinocaine drug.

How does LEUCINOCAINE work?

Leucinocaine is thought to work by interacting with a specific target in the body, but its exact mechanism is not yet understood.

What drug class is LEUCINOCAINE in?

LEUCINOCAINE belongs to the leucinocaine class. See all leucinocaine drugs at /class/leucinocaine.

What development phase is LEUCINOCAINE in?

LEUCINOCAINE is in Phase 2.

Drug class: All leucinocaine drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing